News

Quotient Bioresearch extends agreement with GE Healthcare to complete transfer into new radiochemistry facility in Cardiff

admin — Mon, 18 Jan 2010 15:15:54 +0100

18 January 2010, Cambridgeshire, UK: An extension to the manufacturing transfer agreement that was put in place with GE Healthcare (GEHC) as part of the Quotient Bioresearch acquisition of Amersham Radiolabelling Services, the custom radiochemical synthesis operations of GE Healthcare, has now been agreed. This extension will assure customers of a smooth transition and uninterrupted supply of carbon-14 labelled compounds during the move of Amersham Radiolabelling Services from the existing site to its new state-of-the-art facility in Cardiff this Spring.

Quotient Evidence white paper discusses the role of biomarkers in metabolic syndrome

admin — Wed, 23 Dec 2009 12:06:53 +0100

Quotient Evidence white paper discusses the role of biomarkers in metabolic syndrome

Sharing science - Quotient Bioresearch conference posters at EBF present aspects of best practice

admin — Fri, 27 Nov 2009 12:13:27 +0100

27 November 2009, Fordham, Cambridgeshire, UK: At the upcoming European Bioanalysis Forum, Barcelona, 2-4 Dec 2009, Quotient Bioresearch will feature two significant pieces of recent work. In the posters presented, Quotient experts will pick up on the themes of this year’s event - new and improved methods and methodologies, emerging guidelines, and quality and validation in biomarkers and bioanalysis.

COPD white paper kick-starts new information programme from Quotient Bioresearch

admin — Tue, 24 Nov 2009 14:59:01 +0100

Cambridgeshire, UK, 24 November 2009: The latest addition to Quotient Bioresearch’s ongoing ‘Evidence’ information series is now available for download. Biomarkers in Respiratory Disease – Part 1: Chronic Obstructive Pulmonary Disease (COPD) is the first white paper in a new series that will explore the value that biomarkers can add to drug discovery and development in important therapeutic areas.

Quotient Clinical Demonstrates Effective Drug Product Optimisation with RapidFACT Platform

admin — Thu, 22 Oct 2009 17:57:31 +0200

Cambridgeshire, UK, 26th October 2009 – Quotient Clinical, a strategic business unit of leading drug development services provider Quotient Bioresearch (“Quotient”), today announces the availability of a new white paper demonstrating the advanced capabilities of the novel RapidFACT™ approach: an integrated formulation development, manufacture and clinical testing service. RapidFACT can be used to optimise drug products with significantly shorter timelines and reduced associated expenditure compared to traditional approaches.

QUOTIENT BIORESEARCH TO SHOWCASE ITS LEADING-EDGE TECHNOLOGIES AND SERVICES AT 2009 AAPS ANNUAL MEETING AND EXPOSITION

admin — Tue, 13 Oct 2009 17:21:31 +0200

Cambridgeshire, UK, 8th October 2009 – Quotient Bioresearch (“Quotient”), a leading provider of early drug development services, will be showcasing the breadth of its leadingedge technologies and services for early drug development at the American Association of Pharmaceutical Scientists (AAPS) 2009 Annual Meeting and Exposition, on booth #2446.

Quotient Bioresearch supports key industry trend with comprehensive biomarker services for drug development

admin — Thu, 01 Oct 2009 09:43:33 +0200

30 September 2009, Fordham, Cambridgeshire, UK. A commercial pioneer of biomarkers in drug development, Quotient Bioresearch offers valuable know-how in marker development, the establishment and validation of methods, and routine quantification of close to 250 different biomarkers. The company has one of the largest and best equipped bioanalytical and biomarker facilities in Europe.

Quotient delivers new insight into safety and efficacy of cardiovascular, diabetes and obesity drugs

admin — Thu, 01 Oct 2009 09:21:30 +0200

30 September 2009, Fordham, Cambridgeshire, UK. Data from Quotient Bioresearch’s new extended lipid marker screen for assessing drug safety and efficacy was presented at the Institute of Biomedical Sciences (IBMS) annual congress in Birmingham (UK) this week
(28 – 30 September 2009). The range of markers included in the rapid screen extends the basic biochemistry panel currently used and provides a more comprehensive insight into the safety and efficacy of new drug compounds being evaluated for Coronary Vascular Disease (CVD), Coronary Heart Disease (CHD), diabetes and obesity.

Drug Metabolism Discussion Group meeting 2009: Quotient Bioresearch to present

admin — Fri, 11 Sep 2009 14:12:18 +0200

Dr Steve Pleasance, Managing Director of Bioanalytical Sciences, Quotient Bioresearch, is presenting on 'Challenges in the validation of LC-MS methods for protein quantitation' at the 2009 DMDG Open Meeting (23 - 25 September).

Quotient Bioresearch announce collaboration with Clinical Reference Laboratory for central laboratory services for global clinic

admin — Mon, 24 Aug 2009 14:40:19 +0200

Quotient Bioresearch Limited (Cambridgeshire, UK), a leading provider of drug development services, and Clinical Reference Laboratory (CRL); Kansas, USA, a privately owned reference laboratory offering leading edge testing services, have concluded an agreement that will result in the immediate provision of global clinical laboratory testing for drug development clinical trials to clients world wide.

Download Press Release